Trial Outcomes & Findings for Comparison of Blood Pressure Medications on Metabolism (NCT NCT00642434)

NCT ID: NCT00642434

Last Updated: 2023-12-26

Results Overview

Reporting the number of participants with a change in markers of inflammation (PAI-1) following treatment compared to baseline.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

22 participants

Primary outcome timeframe

5 months

Results posted on

2023-12-26

Participant Flow

Participant milestones

Participant milestones
Measure
Metoprolol
Randomized to Metoprolol
Carvedilol
Radomized to Carvedilol
Overall Study
STARTED
10
12
Overall Study
Number of Participants Treated
10
12
Overall Study
COMPLETED
10
12
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Data were not collected

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Number of Participants Treated With Metoprolol
n=9 Participants
Randomized to Metoprolol
Number of Participants Treated With Carvedilol
n=11 Participants
Radomized to Carvedilol
Total
n=20 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=9 Participants
0 Participants
n=11 Participants
0 Participants
n=20 Participants
Age, Categorical
Between 18 and 65 years
9 Participants
n=9 Participants
11 Participants
n=11 Participants
20 Participants
n=20 Participants
Age, Categorical
>=65 years
0 Participants
n=9 Participants
0 Participants
n=11 Participants
0 Participants
n=20 Participants
Sex: Female, Male
Female
0 Participants
Data were not collected
0 Participants
Data were not collected
0 Participants
Data were not collected
Sex: Female, Male
Male
0 Participants
Data were not collected
0 Participants
Data were not collected
0 Participants
Data were not collected

PRIMARY outcome

Timeframe: 5 months

Reporting the number of participants with a change in markers of inflammation (PAI-1) following treatment compared to baseline.

Outcome measures

Outcome measures
Measure
Metoprolol
n=9 Participants
Randomized to Metoprolol
Carvedilol
n=11 Participants
Radomized to Carvedilol
Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline
0 participants
0 participants

Adverse Events

Metoprolol

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Carvedilol

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Kathleen Colleran

University of New Mexico Health Sciences Center

Phone: 505-272-4658

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place